Adult‐onset inflammatory myopathy: North Canterbury experience 1989–2001
- 25 February 2005
- journal article
- research article
- Published by Wiley in Internal Medicine Journal
- Vol. 35 (3), 170-173
- https://doi.org/10.1111/j.1445-5994.2004.00764.x
Abstract
To perform a clinical audit of all patients diagnosed with inflammatory myopathy in the North Canterbury region. A retrospective case note audit of patients with a discharge diagnosis of inflammatory myopathy from June 1989 to June 2001 was performed. The audit was based at Christchurch Hospital, New Zealand, which services a population of 430,000. Of 77 case notes reviewed, 44 patients were identified who were considered to fulfil clinical criteria for inflammatory myopathy. There was a female preponderance (80% female, 20% male). Diagnostic categories in descending order of frequency included: dermatomyositis (41%), polymyositis (39%), inclusion body myositis (IBM) (14%) and overlap syndromes (6%). Malignancy-associated myositis occurred in 20% overall (dermatomyositis 11%, polymyositis 9%). Delays in diagnosis and late age at presentation (average 72 years) were seen in the IBM group. Proximal limb weakness was common, but not universal at presentation (80%). A muscle biopsy was performed in all patients and electromyography in 82%. All were treated with high dose prednisone (0.5-1 mg/kg) of whom 29% were maintained on prednisone alone. Immunosuppressives/immunomodulators used included: azathioprine (58%), methotrexate (31%), intravenous immunoglobulin (13%), chlorambucil (13%), and cyclophosphamide (9%). Thirteen patients (42%) required more than one agent, with three trialling five agents. There were 59 relapses in 20 patients (45%), with mean time to first relapse of 7.8 months. At audit completion, 33% had deceased with malignancy and respiratory failure the main causes. Inflammatory myopathy is a challenging condition in both diagnosis and management. Our audit has shown delays in the diagnosis of IBM, a relatively high incidence of malignancy and a notable risk of relapse and mortality.Keywords
This publication has 18 references indexed in Scilit:
- O97 Polymyositis and dermatomyositis: short-term and long-term outcome, and predictive factors of prognosisEuropean Journal of Internal Medicine, 2003
- When and How Should the Patient With Dermatomyositis or Amyopathic Dermatomyositis Be Assessed for Possible Cancer?Archives of Dermatology, 2002
- Routine vs Extensive Malignancy Search for Adult Dermatomyositis and PolymyositisArchives of Dermatology, 2002
- Rhabdomyolysis: A reviewMuscle & Nerve, 2002
- Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based studyThe Lancet, 2001
- Magnetic resonance imaging of skeletal muscles in idiopathic inflammatory myopathies of adultsZeitschrift für Neurologie, 1994
- A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for DermatomyositisNew England Journal of Medicine, 1993
- Risk of Cancer in Patients with Dermatomyositis or PolymyositisNew England Journal of Medicine, 1992
- Polymyositis, Dermatomyositis, and Inclusion-Body MyositisNew England Journal of Medicine, 1991
- Polymyositis and DermatomyositisNew England Journal of Medicine, 1975